Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5622659 | 0.89 | ACHE (0.45) | EGFRNPC1RAB9ASMN1; SMN2CASP3 | |
| SCHEMBL3262111 | 0.87 | ESR2 (0.52) | NPC1RAB9ASMN1; SMN2CASP3SENP7 | |
| SCHEMBL11205461 | 0.87 | APP (0.39) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5322041 | 0.87 | MAOB (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4468568 | 0.87 | MEN1 (0.40) | RAB9ASMN1; SMN2TP53MAPK1HSD17B1 | |
| SCHEMBL6841236 | 0.87 | MEN1 (0.38) | CA1CA2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10918406 | 0.87 | CYP11B1 (0.44) | NPC1RAB9ASMN1; SMN2ABL1ABCB1 | |
| SCHEMBL8327622 | 0.87 | MAOB (0.43) | NPC1RAB9ATP53MAOBAPP | |
| SCHEMBL7033071 | 0.86 | CA4 (0.43) | NPC1RAB9ASMN1; SMN2TP53ABCB1 | |
| SCHEMBL28095381 | 0.86 | ABL1 (0.47) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2336144-B1 | ESTERIFIED ALPHA-GALACTOSYLCERAMIDE | RIKEN (JP) | 2015-01-21 | — | — | EP | disclosed |
| EP-2780326-A1 | METHOD FOR INHIBITION OF DEUBIQUITINATING ACTIVITY | Vivolux Ab (SE) | 2014-09-24 | — | — | EP | disclosed |
| US-8580751-B2 | Esterified α-galactosylceramide | RIKEN (JP) | 2013-11-12 | — | — | US | disclosed |
| WO-2013058691-A1 | METHOD FOR INHIBITION OF DEUBIQUITINATING ACTIVITY | VIVOLUX AB (SE) | 2013-04-25 | — | — | WO | disclosed |
| US-20110224158-A1 | ESTERIFIED ALPHA-GALACTOSYLCERAMIDE | RIKEN (JP) | 2011-09-15 | — | — | US | disclosed |
| EP-2344453-A2 | ACTIVATORS OF HUMAN PYRUVATE KINASE | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2336144-A1 | ESTERIFIED ALPHA-GALACTOSYLCERAMIDE | Riken (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110046397-A1 | NEW PROCESSES | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| CN-101768042-A | Method for preparing polysubstituted indene skeleton derivative | UNIV FUDAN | 2010-07-07 | — | — | CN | disclosed |
| WO-2010042867-A2 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-04-15 | — | — | WO | disclosed |
| EP-1370528-B1 | MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY | SCHERING CORP (US) | 2005-06-08 | — | — | EP | disclosed |
| US-5749925-A | Dyeing or printing process with new and known cationic 4,5-dihydro-iH-1,2,3-triazolium compounds as dyestuffs and new cationic 4,5-dihydro-1H-1,2,3-triazolium compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1998-05-12 | — | — | US | disclosed |
| US-5573909-A | DETECTING MULTIPLE DIFFERENT TARGET SPECIFIC BINDING PAIR MEMBER IN SAMPLE BY USING PROBES COMPRISING POLYMERIC MICROPARTICLE CONTAINING DISPERSED SERIES OF FLUORESCENT DYES, AND COMPLEMENTARY SPECIFIC BINDING PAIR MEMBER | MOLECULAR PROBES, INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5134150-A | Administering diaryl-substituted imidazothiazoles; antiarthritic agents | SMITHKLINE BEECHAM CORPORATION (US) | 1992-07-28 | — | — | US | disclosed |
| US-4686231-A | 4,5-DIARYL-2-SUBSTITUTED-IMIDAZOLE | SMITHKLINE BECKMAN CORPORATION (US) | 1987-08-11 | — | — | US | disclosed |
| US-4110460-A | ANTIINFLAMMATORY, ANALGESIC | METABIO (FR) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046397-A1 | NEW PROCESSES | MME, REN, AGTR1 | CA12 4102/4885CA1 2624/4885CA2 859/4885 |
| US-20110224158-A1 | ESTERIFIED ALPHA-GALACTOSYLCERAMIDE | GBA1, UGCG, MAN2B1 | CA12 85/4885CA1 207/4885CA2 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.